Roche's Subcutaneous Ocrevus Rivals IV Formulation in Phase III MS Trial
The subcutaneous version of its blockbuster multiple sclerosis drug notched a victory in a key late-stage study. Roche will submit the OCARINA II data to global health authorities in the coming months.
Levi Garraway Novarti Kesimpta Roche Genentechclaimed Roche Building Oches Subcutaneous Ocrevus Rivals Iv Formulation In Phase Iii Ms Trial
Source: biospace.com